Indication name: Von Willebrand disease (VWD)
Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market
Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US,
Germany, France, Spain, United Kingdom, Italy, Japan & China).
Von
Willebrand disease (VWD)
is a blood disorder in which the blood does not clot properly. VWD is a genetic
disorder caused by missing or defective von Willebrand factor (VWF), a clotting
protein. VWF binds factor VIII, a key clotting protein, and platelets in blood
vessel walls, which help form a platelet plug during the clotting process. The
VWF gene is located on the short arm (p) of chromosome 12 (12p13). The VWF gene
regulates (encodes) VWF. Mutations to this gene result in low levels of VWF, or
in VWF that is defective and doesn’t function properly.
Classification-
Type 1- most common and mildest form of VWD, low levels of factor VIII, about
85% of people treated for VWD have Type 1.
Type 2- the body makes normal amounts of the VWF but the factor does not
work the way it should, four subtypes― 2A, 2B, 2M, and 2N―depending on the
specific problem with the person’s VWF.
Type 3- most severe form of VWD, in which a person has very little or no
VWF and low levels of factor VIII. Only 3% of people with VWD have Type 3.
Epidemiology- Thelansis estimates, VWD is the most common bleeding
disorder, found in up to 1% of the U.S. population. This means that 3.2 million
(or about 1 in every 100) people in the United States have the disease. VWD
occurs among men and women equally, women are more likely to notice the
symptoms because of heavy or abnormal bleeding during their menstrual periods
and after childbirth.
Competitive landscape of Von Willebrand disease (VWD) includes country
specific approved as well as pipeline therapies. Any asset/ product specific
designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
KOLs insights of Von Willebrand disease (VWD) across 8 MM market from
center of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
Von Willebrand disease (VWD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which
Data Inputs with sourcing, Market Event and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Phase
1 Factor VIII + von
Willebrand factor complex Octapharma Launched
2 Factor VIII Baxter Launched
3 Alphanate Grifols Launched
4 Aleviate CSL Limited Launched
5 8Y; Factor VIII/von
Willebrand Factor Bio Products
Laboratory Launched
6 Humate-P CSL Limited Launched
7 von Willebrand factor LFB Launched
8 vonicog alfa Baxter Launched
9 human von Willebrand factor China Biologic Products Phase I
No comments:
Post a Comment